Grifols | GRFS - Selling And Administration Expenses


Grifols reported EUR320.45M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Alaunos Therapeutics USD 585K 84K Sep/2025
Arca Biopharma USD 2.23M 1.08M Dec/2025
aTyr Pharma USD 82.26M 77.46M Dec/2025
Bio Path USD 199K 300K Sep/2025
Brainstorm Cell Therapeutics USD 1.39M 326K Dec/2025
Capricor Therapeutics USD 1.92M 446.47K Dec/2025
Cara Therapeutics USD 2.19M 2.45M Sep/2025
Esperion Therapeutics USD 39.42M 456K Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Grifols EUR 320.45M 12.65M Dec/2025
Immunic USD -0.24 0.03 Sep/2024
Infinity Pharmaceuticals USD 3.75M 2.19M Jun/2023
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
TherapeuticsMD USD 1.23M 90K Jun/2024